noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Kirkland & Ellis LLP

Private Equity/M&A Partner Adam Prince Joins Kirkland & Ellis
Oakland University

Natalie Ishioka named Student of the Year by the Great Lakes Affiliate[...]
ImmuCell Corporation

2025 Form 10-K (proofs 0000811641 118730 ALL DOCS clean pn120)

Healthcare

Pappas Capital LLC

11/14/2007 | Press release | Archived content

LEAD Therapeutics announces strategic research collaboration with...

News | 11. 14. 2007

LEAD Therapeutics

LEAD Therapeutics, Inc., a chemistry-driven drug discovery company based in the San Francisco Bay Area, today announced it has entered into a strategic research collaboration with Shanghai ChemPartner in China, the wholly owned subsidiary of ShangPharma. In conjunction with this collaboration, China Gateway Life Science (Holding) Ltd., the strategic investment arm of ShangPharma, has made an equity investment in LEAD Therapeutics. Previously announced investors include Pappas Ventures, ProQuest Investments, and Mustang Ventures.

Pappas Capital LLC published this content on November 14, 2007, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format